Studies whether certain diabetes and weight medicines are linked to medullary thyroid cancer
Compares medullary thyroid cancer rates in people taking GLP-1 medicines versus other treatments.
Plain-language title generated from the registry record
Registry title: Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
Key facts
- Where
- Parsippany, United StatesSee the site
Where in United States
- IQVIAParsippany, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07713901
- Record updated
- 4 August 2026
- Original description
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.Read full original descriptionShow less
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.
Inclusion: 18 years or older during the year of index (date of qualifying medication); In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1; ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period); No evidence of cohort qualifying medication during 12-month before the index date; Reside in the US, including the District of Columbia (DC) during the study period; No missing values for year of birth.
Exclusion: Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.